SPD 554

Drug Profile

SPD 554

Alternative Names: Guanfacine Carrier Wave project; SPD-554

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire
  • Class Anxiolytics
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Attention-deficit hyperactivity disorder; Autistic disorder

Most Recent Events

  • 30 Jun 2013 Discontinued - Phase-I for Anxiety disorders (in children) in Ireland (unspecified route)
  • 30 Jun 2013 Discontinued - Phase-I for Autistic disorder in Ireland (unspecified route)
  • 31 Dec 2012 Discontinued - Phase-I for Attention-deficit hyperactivity disorder in Ireland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top